156 related articles for article (PubMed ID: 37276599)
21. Pharmacogenomics: Prescribing Precisely.
Wake DT; Ilbawi N; Dunnenberger HM; Hulick PJ
Med Clin North Am; 2019 Nov; 103(6):977-990. PubMed ID: 31582008
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics of Adverse Drug Reactions.
Osanlou O; Pirmohamed M; Daly AK
Adv Pharmacol; 2018; 83():155-190. PubMed ID: 29801574
[TBL] [Abstract][Full Text] [Related]
23. Strategies for Avoiding Benzopyrone Hepatotoxicity in Lymphedema Management-The Role of Pharmacogenetics, Metabolic Enzyme Gene Identification, and Patient Selection.
Hu M; Piller NB
Lymphat Res Biol; 2017 Dec; 15(4):317-323. PubMed ID: 29087786
[TBL] [Abstract][Full Text] [Related]
24. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.
van der Wouden CH; Böhringer S; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VHM; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Rial-Sebbag E; Samwald M; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; van Zwet E; Swen JJ; Guchelaar HJ;
Pharmacogenet Genomics; 2020 Aug; 30(6):131-144. PubMed ID: 32317559
[TBL] [Abstract][Full Text] [Related]
25. Making data on essential pharmacogenes available for every patient everywhere: the Medicine Safety Code initiative.
Samwald M; Freimuth RR
Pharmacogenomics; 2013 Oct; 14(13):1529-31. PubMed ID: 24088121
[No Abstract] [Full Text] [Related]
26. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacogenetics and prediction of side effects of drugs].
Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
[TBL] [Abstract][Full Text] [Related]
28. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
Bell GC; Caudle KE; Whirl-Carrillo M; Gordon RJ; Hikino K; Prows CA; Gaedigk A; Agundez J; Sadhasivam S; Klein TE; Schwab M
Clin Pharmacol Ther; 2017 Aug; 102(2):213-218. PubMed ID: 28002639
[TBL] [Abstract][Full Text] [Related]
29. Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation.
Roman YM; Dixon DL; Salgado TM; Price ET; Zimmerman KM; Sargent L; Slattum PW
Pharmacogenomics; 2020 Jun; 21(9):627-635. PubMed ID: 32425117
[TBL] [Abstract][Full Text] [Related]
30. Detection of relevant pharmacogenetic information through exome sequencing in oncology.
Verdez S; Albuisson J; Duffourd Y; Boidot R; Reda M; Thauvin-Robinet C; Fumet JD; Ladoire S; Nambot S; Callier P; Faivre L; Ghiringhelli F; Picard N
Pharmacogenomics; 2022 Sep; 23(14):759-770. PubMed ID: 36043386
[No Abstract] [Full Text] [Related]
31. Considerations of pharmacogenetic testing in children.
Haga SB; Solomon BD
Pharmacogenomics; 2016 Jun; 17(9):975-7. PubMed ID: 27248426
[No Abstract] [Full Text] [Related]
32. [Pharmacogenetics: relevant aspects for the practicing veterinarian].
Jud Schefer R; Paine Kuhn C; Demuth D
Schweiz Arch Tierheilkd; 2012 Dec; 154(12):521-7. PubMed ID: 23188764
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics arrives.
Petsko GA
Genome Biol; 2004; 5(6):108. PubMed ID: 15186481
[TBL] [Abstract][Full Text] [Related]
34. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
35. Genetic predisposition to adverse drug reactions in the intensive care unit.
Empey PE
Crit Care Med; 2010 Jun; 38(6 Suppl):S106-16. PubMed ID: 20502164
[TBL] [Abstract][Full Text] [Related]
36. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
Hachad H; Ramsey LB; Scott SA
Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
[No Abstract] [Full Text] [Related]
37. Pathology consultation on warfarin pharmacogenetic testing.
Stack G;
Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
[No Abstract] [Full Text] [Related]
38. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
Becquemont L
Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.
Elliott LS; Henderson JC; Neradilek MB; Moyer NA; Ashcraft KC; Thirumaran RK
PLoS One; 2017; 12(2):e0170905. PubMed ID: 28151991
[TBL] [Abstract][Full Text] [Related]
40. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
